The fibroblast as a therapeutic target in rheumatoid arthritis.
暂无分享,去创建一个
[1] M. Genovese,et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. , 2013, Arthritis and rheumatism.
[2] J. Dean,et al. The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look , 2012, The open rheumatology journal.
[3] D. Scott. Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis , 2012, Clinical pharmacology and therapeutics.
[4] Georg Schett,et al. The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.
[5] G. Firestein,et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon , 2011, Annals of the rheumatic diseases.
[6] B. Nair,et al. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells , 2011, Breast Cancer Research.
[7] S. Gay,et al. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells , 2011, Annals of the rheumatic diseases.
[8] P. Tak,et al. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts , 2011, Genes and Immunity.
[9] P. Tak,et al. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? , 2011, Autoimmunity reviews.
[10] P. Tak,et al. Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis , 2011, PloS one.
[11] C. Buckley. Why does chronic inflammation persist: An unexpected role for fibroblasts. , 2011, Immunology letters.
[12] N. Karlsson,et al. The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis , 2011, Arthritis Research & Therapy.
[13] J. Tavernier,et al. CD248 and its cytoplasmic domain: a therapeutic target for arthritis. , 2010, Arthritis and rheumatism.
[14] James O. Jones,et al. Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .
[15] A. Filer,et al. Stromal cells differentially regulate neutrophil and lymphocyte recruitment through the endothelium , 2010, Immunology.
[16] M. Esteller,et al. Epigenetic modifications and human disease , 2010, Nature Biotechnology.
[17] M. Hochberg,et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. , 2010, Seminars in arthritis and rheumatism.
[18] R. Gay,et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. , 2010, Arthritis and rheumatism.
[19] P. Tak,et al. Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. , 2010, Arthritis and rheumatism.
[20] G. Herbein,et al. Targeting intracellular signaling pathways to treat rheumatoid arthritis: Pandora's box? , 2010, Joint, bone, spine : revue du rhumatisme.
[21] R. Gay,et al. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. , 2009, Arthritis and rheumatism.
[22] P. Robbins,et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints , 2009, Nature Medicine.
[23] M. Kawai,et al. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway , 2009, Modern rheumatology.
[24] J. Smolen,et al. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. , 2009, Arthritis and rheumatism.
[25] R. Kalluri,et al. Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.
[26] G. Burmester,et al. Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? , 2009, Nature Clinical Practice Rheumatology.
[27] H. Pavenstädt,et al. Cell death in rheumatoid arthritis , 2009, Apoptosis.
[28] Stephen Kelly,et al. Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium , 2009, PLoS medicine.
[29] C. Buckley,et al. Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. , 2008, Arthritis and rheumatism.
[30] R. Gay,et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. , 2007, Arthritis and rheumatism.
[31] M. Takeichi,et al. Cadherin-11 in Synovial Lining Formation and Pathology in Arthritis , 2007, Science.
[32] Georg Schett,et al. Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.
[33] U. Müller-Ladner,et al. Microarrays demystified. , 2004, Environmental health perspectives.
[34] F. M. Thomas,et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. , 2006, The Journal of clinical investigation.
[35] Howard Y. Chang,et al. Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs , 2006, PLoS genetics.
[36] J. Lord,et al. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. , 2006, Arthritis and rheumatism.
[37] G. Christofori,et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. , 2006, Cancer cell.
[38] C. Isacke,et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium , 2005, FEBS letters.
[39] B. Bresnihan,et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis , 2005, European journal of immunology.
[40] D. Patel,et al. Cadherin-11 Provides Specific Cellular Adhesion between Fibroblast-like Synoviocytes , 2004, The Journal of experimental medicine.
[41] A. Otaka,et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti‐rheumatoid arthritis agent , 2004, FEBS letters.
[42] K. Preissner,et al. Human Thy-1 (CD90) on Activated Endothelial Cells Is a Counterreceptor for the Leukocyte Integrin Mac-1 (CD11b/CD18)1 , 2004, The Journal of Immunology.
[43] N. Miyasaka,et al. Gene Transfer of a Cell Cycle Modulator Exerts Anti-Inflammatory Effects in the Treatment of Arthritis 1 , 2003, The Journal of Immunology.
[44] G. Haines,et al. IL-6 and Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts1 , 2003, The Journal of Immunology.
[45] Dominique Schols,et al. AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice1 , 2001, The Journal of Immunology.
[46] W. O'Fallon,et al. Lymphoid Neogenesis in Rheumatoid Synovitis1 , 2001, The Journal of Immunology.
[47] J. Lord,et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. , 2001, Trends in immunology.
[48] T. Kipps,et al. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. , 2001, The Journal of clinical investigation.
[49] R. Gay,et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[50] J. Lord,et al. Persistent Induction of the Chemokine Receptor CXCR4 by TGF-β1 on Synovial T Cells Contributes to Their Accumulation Within the Rheumatoid Synovium1 , 2000, The Journal of Immunology.
[51] J. Kriegsmann,et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. , 1996, The American journal of pathology.
[52] M. Burdick,et al. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. , 1995, Journal of immunology.
[53] M. Burdick,et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. , 1994, The Journal of clinical investigation.
[54] R. Strieter,et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. , 1991, Journal of immunology.
[55] A. Kraneveld,et al. Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. , 2012, Pharmacology & therapeutics.
[56] D. Patel,et al. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.
[57] D. Haskard,et al. Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. , 1993, Laboratory investigation; a journal of technical methods and pathology.